Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo

被引:0
|
作者
Petrylak, D. [1 ]
Eigl, B. [2 ]
Senkus, E. [3 ]
Loriot, Y. [4 ]
Twardowski, P. [5 ]
Castellano, D. [6 ]
Blais, N. [7 ]
Sridhar, S. [6 ,8 ]
Sternberg, C. [9 ]
Retz, M. [10 ]
Blumenstein, B. [11 ]
Jacobs, C. [12 ]
Stewart, P. [13 ]
Bellmunt, J. [14 ]
机构
[1] Yale Canc Ctr, Prostate & Urol Canc Program, New Haven, CT USA
[2] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada
[3] Uniwersyteckie Ctr Klin, Klin Onkol & Radioterapii, Gdansk, Poland
[4] Gustave Roussy Canc Ctr, Dept Canc Med, Villejuif, France
[5] City Hope Natl Med Ctr, Med Oncol, Duarte, CA 91010 USA
[6] Hosp Univ 12 Octubre, Serv Oncol Med, Madrid, Spain
[7] Univ Montreal, Dept Med, CHUM Hop Notre Dame, Montreal, PQ H3C 3J7, Canada
[8] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada
[9] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy
[10] Tech Univ Munich, Urol Klin & Poliklin, D-80290 Munich, Germany
[11] Tri Arc Consulting, Washington, DC USA
[12] OncoGenex Pharmaceut Inc, Clin Res, Bothell, WA USA
[13] OncoGenex Pharmaceut Inc, Clin Dev, Bothell, WA USA
[14] Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA 02115 USA
关键词
D O I
10.1016/S0959-8049(16)31454-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2637
引用
收藏
页码:S525 / S525
页数:1
相关论文
共 1 条
  • [1] First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial
    Bellmunt, Joaquim
    Eigl, Bernhard J.
    Senkus-Konefka, Elzbieta
    Loriot, Yohann
    Twardowski, Przemyslaw
    Castellano, Daniel E.
    Blais, Normand
    Sridhar, Srikala S.
    Sternberg, Cora N.
    Retz, Margitta
    Blumenstein, Brent A.
    Jacobs, Cindy
    Stewart, Patricia S.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)